NovaBridge Biosciences (NBP) Cash & Current Investments (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Cash & Current Investments data on file, last reported at $210.8 million in Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $210.8 million, up 21.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $210.8 million (up 21.59% YoY), and the FY2025 annual result was $210.8 million, up 21.59% from the prior year.
• Cash & Current Investments declined to $210.8 million in Q4 2025 per NBP's latest filing, from $228.3 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $118.4 billion in Q4 2021 and troughed at $165.6 million in Q2 2025.
• A 5-year average of $9.4 billion and a median of $366.2 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2022: Cash & Current Investments surged 16273.69% in 2021, then sank 99.61% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $118.4 billion in 2021, then slumped by 99.61% to $465.5 million in 2022, then tumbled by 31.84% to $317.3 million in 2023, then tumbled by 45.35% to $173.4 million in 2024, then gained by 21.59% to $210.8 million in 2025.
• Business Quant data shows NBP's Cash & Current Investments at $210.8 million in Q4 2025, $228.3 million in Q3 2025, and $165.6 million in Q2 2025.